Novanta (NOVT) Earnings: Q3 2026 Results

The quarter ended October 2, 2026 and Novanta published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Novanta reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted Diluted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Novanta closed its acquisition of Riverpoint Medical on July 23, 2026 for $1,200.6 million of upfront cash, net of cash acquired, plus a $250.0 million milestone payment due by January 8, 2027. Riverpoint added $32.9 million of revenue in Q3 2026 and sits in Medical Solutions.
• Novanta's fiscal quarters end on a Friday: Q3 2026 ended October 2, 2026 and Q3 2025 ended September 26, 2025.

Source: Novanta Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended October 2, 2026. Figures as reported; checked against the release on November 10, 2026.

How Novanta splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Novanta's Automation Enabling Technologies revenue was $145 million in Q3 2026, up 16% from $125 million in Q3 2025, 48% of total revenue.
• Novanta's Medical Solutions revenue was $160 million in Q3 2026, up 30% from $123 million in Q3 2025, 52% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Novanta said:

“For the fourth quarter of 2026, the Company expects GAAP revenue to be in the range of $306 million to $312 million, reflecting reported revenue growth of more than 18%.”

“The Company also expects Adjusted EBITDA to be in the range of $76 million to $79 million and Adjusted Diluted EPS to be in the range of $0.91 to $0.96 per diluted share, or 0% to 5% growth.”

“For the full year 2026, the Company now expects GAAP revenue to be in the range of $1,135 million to $1,140 million, reflecting reported growth of approximately 16%.”

“Looking ahead to 2027, we expect reported revenue growth of more than 15%.”

Source: Novanta Q3 2026 release, Nov 9, 2026.

This is the company's own guidance as of Nov 9, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the NOVT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Novanta's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

Novanta describes itself as a technology partner to medical and advanced technology equipment manufacturers, and reports two segments. Medical Solutions had Q3 2026 revenue of $159.7 million, up from $122.5 million, and Automation Enabling Technologies $145.4 million, up from $125.3 million, for a total of $305.0 million, up 23.1%. (Novanta Q3 2026 release, Nov 9, 2026)

Acquisitions added $32.9 million, or 13.3%, of the growth, all of it from Riverpoint Medical, which Novanta bought on July 23, 2026 for $1,200.6 million upfront. Riverpoint makes minimally invasive surgical consumables, including advanced surgical fibers for sports medicine, trauma and cardiovascular surgery. Organic revenue growth was 9.9%, and currency reduced revenue by $0.3 million. (Novanta Q3 2026 release, Nov 9, 2026; Novanta Form 10-Q, Q3 2026, Nov 9, 2026)

By product capability, Advanced Surgical Technologies was the largest line at $102.1 million, against $61.7 million a year earlier, while Precision Medicine fell to $57.5 million from $60.8 million. In automation, Robotics and Automation brought in $94.0 million and Precision Manufacturing $51.4 million. (Novanta Form 10-Q, Q3 2026, Nov 9, 2026)

Customers in the United States accounted for $150.6 million of Q3 2026 revenue. Germany contributed $36.5 million, the rest of Europe $44.7 million, China $30.3 million and the rest of Asia-Pacific $32.0 million. Novanta said customer bookings rose 29% and backlog reached $543 million. (Novanta Form 10-Q, Q3 2026, Nov 9, 2026; Novanta Q3 2026 release, Nov 9, 2026)

Novanta's GAAP diluted EPS fell to $0.05 in Q3 2026 from $0.30, while Adjusted Diluted EPS rose 20.7% to $1.05. The gap is mostly acquisition accounting and deal costs: $21.4 million of amortization of intangible assets, $19.2 million of acquisition and related costs, $3.9 million of restructuring and $800 thousand of inventory fair value adjustments, plus $3.7 million for planning a new financial and operating system. (Novanta Q3 2026 release, Nov 9, 2026)

The GAAP effective tax rate was 68.2%, on income before taxes of $6.3 million. Net interest expense rose to $8.3 million from $6.0 million after Novanta borrowed $626.0 million under its senior credit facilities in the quarter, when it also paid $1,200.6 million for Riverpoint. (Novanta Q3 2026 release, Nov 9, 2026)

Diluted weighted average shares rose to 42,709 thousand from 36,040 thousand. In November 2025 Novanta issued 12,650,000 tangible equity units for $632.5 million, each including a prepaid stock purchase contract, and in 2026 it issued 2,143 thousand common shares in a private placement for $288.0 million net. (Novanta Q3 2026 release, Nov 9, 2026; Novanta Form 10-Q, Q3 2026, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Novanta guides the next quarter and full year in its release, on GAAP revenue and non-GAAP earnings. For Q4 2026 it expects revenue of $306 million to $312 million, Adjusted EBITDA of $76 million to $79 million and Adjusted Diluted EPS of $0.91 to $0.96. For 2026 it expects revenue of $1,135 million to $1,140 million, Adjusted EBITDA of $274 million to $277 million and Adjusted Diluted EPS of $3.66 to $3.71, and for 2027 reported revenue growth of more than 15%. (Novanta Q3 2026 release, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover Novanta, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Novanta's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning NOVT is on is NOVT a buy or a sell?, what analysts expect next is on the NOVT forecast, and what the company does is on the Novanta (NOVT) stock page.

Every number on this page can be traced to a document Novanta published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.